Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates

Press release content from Business Wire. The AP news staff was not involved in its creation.

Read the full article here

Related Articles